23 articles for R Jones
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
Pfizer
Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.
King'S College London
Discovery of quinazoline HPK1 inhibitors with high cellular potency.
Emd Serono Research & Development Institute
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
Emd Serono Research & Development Institute
Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Emd Serono Research & Development Institute
The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
Pfizer
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
Gilead Sciences
Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines.
University College London
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Emd Serono Research & Development Institute
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
Emd Serono Research & Development Institute
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
Emd Serono Research & Development Institute
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.
Pfizer
NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO
Emory University
Compounds as inhibitors of DNA methyltransferases
FundaciÓN Para La InvestigaciÓN MÉDica Aplicada